item management s discussion and analysis of financial condition and results of operations 
the following discussion of the financial condition and results of operations should be read in conjunction with the financial statements and the notes thereto included in item a of this annual report on form k 
overview impath was founded in and has become a leader in providing critical information essential for making medically optimal and cost effective cancer management decisions for individual cancer patients 
the company is focused exclusively on the analysis of cancer  combining advanced technologies and medical expertise to provide patient specific diagnostic  prognostic and treatment information to physicians involved in the treatment of cancer 
with expected medical cost increases attributable to the growth in the number of cancer patients and the high cost of new therapies  the company anticipates significant and growing demand for cancer management information 
impath has established its leadership and reputation through its extensive expertise  its integration of technological advances  its emphasis on customer service and education and the cost effectiveness of its services 
the company s revenues  which have increased an average of approximately annually since  have been derived from performing specialized cancer analyses for which impath typically bills various third party payors  such as private insurance plans  managed care plans and governmental programs eg  medicare  as well as hospitals and individual patients 
over the last few years  the company has experienced increased pressures on reimbursement and expects such pressures to cause reduced unit pricing for diagnostic and prognostic analyses in future periods 
the revenue generated from private insurance and managed care has increased significantly as a percentage of total revenue in the last three years as a result of increased focus by the company s sales force on oncology offices as well as a desire by the company s hospital clients to have the company bill third parties directly 
despite those pressures  the company has experienced increasing average reimbursement trends due to changes in its product mix and application of new technologies 
the company also derives revenues by licensing its tumor registry software to community hospitals and state agencies as well as providing contract laboratory services and cancer database and pharmacoeconomic information to pharmaceutical companies 
the following table sets forth the percentages of total revenues represented by certain items reflected in the company s consolidated statements of operations 
the company s business generally has been unaffected by seasonality  except for slower growth in revenues during the third quarter of its fiscal year due to reduced summertime activity 
years ended december  total revenues operating expenses salaries and related costs selling  general and administrative depreciation and amortization total operating expenses operating income net income recent acquisitions on july  the company purchased certain assets of biologic immunologic science laboratories  inc bis  a privately held cancer diagnostics company based in reseda  california for million 
the terms provided for an initial payment of million  and  payable in three equal semi annual installments beginning december  after which another  is payable in three equal semi annual installments contingent on achievement of previously established revenue targets  with interest accruing at per annum 
this transaction will allow impath to expand its core diagnostic and prognostic business and build on impath s scientific leadership in lymph node and bone marrow micrometastases detection in early and late stage cancer 
additionally  bis will further enhance the company s ability to provide unique cancer information to physicians for evaluating and treating cancer patients and to the biopharmaceutical industry in assessing biologically relevant characteristics for targeted drug development and in selecting patients for clinical trials and in evaluating the efficacy of various therapies 
on august  the company acquired medical registry services  inc mrs for the issuance of  shares of impath common stock valued at million 
the company and mrs  which at the time of the acquisition had approximately common clients  began a relationship through a strategic joint venture in january  after the consideration of certain other expenses related to the acquisition and after recording net tangible assets of mrs  the company recorded approximately million in intangibles 
mrs is a leading developer and marketer of cancer registry software products that are currently utilized in over hospitals throughout the united states 
the products are used to collect and manage critical diagnostic  treatment  follow up and outcomes data on cancer patients 
this data stream provides therapeutic  treatment and outcomes information which can be paired with impath s biological and molecular data  creating an unparalleled continuum of care profile from diagnosis to treatment and through follow up 
the database adds value to all the participants involved in treating cancer  from the providers of health care to the patients who receive it 
mrs s revenues are derived from licensing fees paid by hospitals utilizing its proprietary tumor registry software 
on september  the company acquired physician choice  inc pci for the sum of million  with  payable immediately  an additional  payable in four equal semi annual installments beginning march  with interest accruing at per annum and  payable in impath common stock 
an initial  shares of common stock  having a fair market value of  were issued on september    shares of common stock  having a fair market value of  were issued on september    shares of common stock  having a fair market value of  were issued on september  with the remaining shares to be issued on september  pci is a leading provider of post clinical  pre marketing  cost benefit analyses to pharmaceutical and biotechnology companies in connection with new oncology drugs entering the marketplace 
by focusing on cancer  and utilizing health care outcomes and other efficacy measures  pci has achieved a better understanding of the way healthcare is delivered in that specialty 
pci s revenues are generated on a per project basis from pharmaceutical and biotechnology companies 
on august  the company acquired certain assets of bioclinical partners  inc bcp  for million cash  and the issuance of  shares after the for stock split of impath common stock valued at  the terms provided for an initial payment of million  and million payable in three equal annual installments beginning august   contingent on achievement of previously established revenue targets  with interest accruing at per annum 
on september  the terms were amended to provide for an initial payment of million and million payable in installments of  on september  and  on january  as well as contingent payments based upon the achievement of previously established revenue targets  with interest accruing at per annum 
the shares were issued in two installments 
the first installment of  shares after the for stock split was issued on january  and the remaining  shares after the for stock split will be issued on january  bcp is a global medical research network that obtains and provides access to benign and malignant tissue and clinically relevant peripheral blood specimens to support oncology research and product development 
this strategic acquisition provides impath with another critical component in the oncology drug discovery process and extends the range of services provided through biopharma 
on november  the company purchased certain assets of pacific coast reference laboratories  inc pcrl  for up to million cash  with million payable immediately and an additional  payable in four equal semi annual installments beginning may  contingent on achievement of previously established revenue targets  with interest accruing at per annum 
pcrl is a california based  oncology focused testing facility specializing in anatomic pathology utilizing immunohistochemistry and flow cytometry technologies 
on june  the company purchased certain assets of mit consultant  inc mit  a privately held histology business based in los angeles  ca for  the terms provided for an initial payment of  and  payable in two equal semi annual installments beginning november   of which is contingent upon the achievement of previously established revenue targets  with interest accruing at per annum 
on june  the company purchased certain assets of interscience diagnostic laboratories  inc idl  a privately held cytogenetics company based in brooklyn  new york for  this transaction will allow impath to expand its cytogenetics business 
additionally  idl will further enhance the company s ability to provide unique cancer information to physicians for evaluating and treating cancer patients 
the aforementioned acquisitions have been accounted for using the purchase method with results of operations of the respective entities being included with the results of the company since the respective acquisition dates 
the excess of the purchase price over the net assets acquired on bis  pci  bcp  pcrl  mit and idl acquisitions principally relate to customer lists  which are included in intangible assets on the company s consolidated balance sheet and are being amortized over periods of up to fifteen years 
the excess of the purchase price over the net assets acquired for the mrs purchase primarily relates to the customer list  trade name  software and goodwill which are included in intangible assets on the accompanying balance sheets and are being amortized over periods of to years 
recent investment on september  the company completed a million investment in a private placement of preferred stock in ilex oncology service  inc ilex 
ilex is a drug development company focused exclusively on accelerated development of drugs for the treatment and management of cancer 
this investment accrues dividends per share at the rate per annum of and is convertible into common shares of ilex s parent company  ilex oncology inc on november  the company converted the investment into  shares of ilex oncology inc common stock 
the company sold the stock for a pre tax gain of approximately million 
year ended december  compared with year ended december  the company s total revenues for the years ended december  and were million and million  respectively  representing an increase of million  or  in this growth was primarily attributable to an increase in case volume resulting from increased sales and marketing activities  as well as a increase in revenue realization per case due to continuing product mix changes toward lymphoma leukemia cases  which entail more analyses 
in addition  biopharma revenues increased over prior year billings as a result of the successful integration of the recently acquired bcp and increases in the numbers of projects with genomics companies 
salaries and related costs for the years ended december  and were million and million  respectively  representing an increase of million  or  in this increase was the result of increased personnel due to rapid case volume growth and the shift to more complex cases  labor costs associated with the company s recent acquisitions and staff augmentation required to facilitate billing and collection efforts 
salaries and related costs  as a percentage of total revenues  decreased to in from in this decrease was facilitated by the company s successful expansion strategy resulting in streamlining of operational and administrative duties combined with a higher revenue realization per case 
selling  general and administrative expenses for the years ended december  and were million and million  respectively  representing an increase of million  or  in the largest component of this increase was million of increased bad debt expense associated with higher revenues 
additionally  a one time charge of million was recorded for a settlement of a dispute  and related legal fees associated with a prior acquisition 
operating expenses increased by million in connection with recent acquisitions and costs of million were incurred in association with the building of the infrastructure to support increasing demand for our biopharmaceutical genomics services 
the company also incurred an additional million in rental  repairs and equipment service costs as well as million in incremental laboratory supplies  courier costs  temporary services and travel expenses due to rapid case volume growth  facilities expansion and sales and marketing activities 
selling  general and administrative expenses as a percentage of revenues  increased to in from in primarily due to the one time expenses 
depreciation and amortization expense for the years ended december  and was million and million  respectively  representing an increase of million  or  in this increase was primarily due to million in depreciation expense associated with the company s clinical and billing systems  an additional  in depreciation in connection with the expansion of our facilities and  in amortization of intangible assets associated with recent acquisitions 
as a percentage of total revenues  depreciation and amortization expense decreased to in from in income from operations for the years ended december  and was million and million  respectively  representing an increase of million  or  in the figure reflects an increase in operating margins associated with the company s core physician services business  partially offset by the one time expenses of million associated with the settlement of a dispute associated with a prior acquisition 
as a percentage of total revenues  income from operations increased to in from in other income  net for the years ended december  and was million and million  respectively  representing an increase of million in the increase was primarily the result of a gain of million associated with the sale of of the company s investment in ilex partially offset by increased interest expense due to additional capital lease obligations and acquisition related debt  as well as reduced interest income due to the sale of interest bearing securities  the proceeds of which were used to finance the company s stock buyback program and recent acquisitions 
the tax provision for the year ended december  of approximately million reflects federal  state and local income tax expense 
the effective tax rate for was compared to in the increased effective tax rate resulted from an increase in the company s state and local tax provision primarily due to lower tax exempt interest income 
net income for the years ended december  and was million and million  respectively  representing an increase of million  or  in as a percentage of total revenues  net income decreased to in from in this decrease was primarily due to lower interest income  increased interest expense associated with capital lease obligations and acquisition related debt  as well as a higher tax rate 
year ended december  compared with year ended december  the company s total revenues in and were million and million  respectively  representing an increase of million  or  in this growth was primarily due to a increase in case volume resulting from increased sales and marketing activities and a increase in revenue realization per case due to the continuing product mix shift toward cases which carry higher reimbursement rates 
in addition  revenues increased as a result of the successful integration of the company s recent acquisitions 
salaries and related costs in and were million and million  respectively  representing an increase of million  or  in this increase was primarily due to personnel costs associated with the company s case volume growth as well as increases in personnel resulting from the company s recent acquisitions 
as a percentage of total revenues  salaries and related costs decreased to in from in this decrease was facilitated by the company s successful expansion strategy resulting in streamlining of operational and administrative duties combined with a higher revenue realization per case 
selling  general and administrative expenses in and were million and million  respectively  representing an increase of million  or  in the largest component of this increase was million in incremental supply costs associated with rapid case volume growth  recent acquisitions and the continuing product mix shift towards lymphoma leukemia testing which requires more analyses per case 
the company also recorded million of increased bad debt expense associated with higher revenues  and the billing and collection delays associated with the new billing system 
additionally  million of the increase in selling  general and administrative expenses was a result of increased operating expenses incurred in connection with the company s recent acquisitions 
as a percentage of total revenues  selling  general and administrative expenses decreased to in from in due to the implementation of certain operating efficiencies combined with a higher revenue realization per case 
depreciation and amortization in and was million and million  respectively  representing an increase of million  or  in this increase was due to approximately  in intangible amortization associated with the purchase of certain assets of mrs  an additional  in amortization associated with new york facility leasehold improvements and  in amortization expenses associated with the company s new clinical and billing systems which were implemented in as a result of these factors  depreciation and amortization expenses as a percentage of revenues increased to in compared to in income from operations in and was million and million  respectively  representing an increase of million  or  in the figure reflects an increase in bad debt expense associated with billing and collection delays related to the company s billing system s conversion  as well as increased amortization expense in connection with the company s new information system and intangible amortization associated with company acquisitions 
as a result  as a percentage of total revenues  income from operations decreased to in from in other income  net for and was million and million  respectively  representing a decrease of approximately million in the decrease was the result of increased interest expense primarily due to additional capital lease obligations and acquisition related debt  as well as the sale of interest bearing securities  the proceeds of which were used to finance the company s stock buyback program  the acquisition of certain assets of bcp  certain assets of pcrl and the company s preferred stock investment in ilex 
the tax provision for of approximately million reflects federal  state and local income tax expense 
the effective tax rate for was compared to in this increase resulted from an increase in the company s state and local tax provision associated with a reduction in tax exempt interest income 
net income in and was million and million  respectively  representing an increase of million  or  in as a percentage of total revenues  net income decreased to in from in primarily due to the higher depreciation and amortization costs and lower interest income 
liquidity and capital resources since inception  the company has raised approximately million of capital through the public offerings of its common stock and million from private placements of preferred stock  all of which was converted into common stock at the closing of the company s initial public offering in february the company s working capital and capital expenditure needs have increased and are expected to continue to increase as the company expands its existing facilities and pursues its growth strategy 
see business company strategy 
the company s cash and cash equivalent balances at december  and december  were million and million  respectively  representing an increase of million in the company also had approximately million in marketable securities at december   representing a million decrease from the million at december  the net increase in cash and cash equivalents and marketable securities was primarily due to an increase in operating cash flow driven by higher net income partially off set by a m increase in capital expenditures as well as the repurchase of  shares of common stock split adjusted for approximately million associated with the company s treasury stock buyback program 
for the years ended december   net cash provided by operating activities was approximately million which excluded the gain on the sale of ilex stock 
had the gain been included  operating activities would have been million 
operating income was driven by income from operations of approximately m million  partially offset by increases in accounts receivable  net of allowance for bad debt of million 
the increase in net accounts receivable was due primarily to rapid sales growth 
the continuing product mix shift towards lymphoma leukemia cases  which carry a higher revenue realization per case  also contributed to the increase 
in addition  due to rapid case volume growth  lab supplies inventory increased approximately million 
during  the company incurred approximately million in capital expenditures associated with the expansion of its laboratory and office facilities 
the company also received million from short term line of credit bank borrowings and approximately million through the issuance of common stock upon the exercise of company stock options and warrants 
the company has a line of credit for an aggregate principal amount of million with fleet bank 
borrowing under the line bears interest at libor plus 
as of december   the company had million outstanding under this line 
the company has lines of credit for financing equipment  leasehold improvements and computer hardware and software 
in july  the company established a million credit line with newcourt financial currently cit group with lease terms that are based on monthly payments at a rate equal to 
above yield on four year treasury notes 
as of december   the company had fully drawn against this line 
in september  the company established a million credit line with fleet bank with lease terms based on monthly payments at a rate equal to 
above the yield on four year treasury notes 
as of december   approximately million was drawn against the line 
in december  the company established a million credit line with first american bankcorp  inc with lease terms of months and a rate equal to the yield on four year treasury notes 
the line of credit was subsequently increased to million in march  under the same lease terms 
as of december   approximately million was drawn against this line 
in april  the company established an  credit line with dynamics commercial funding corp 
with lease terms of months and a rate equal to the yield on three year treasury notes 
as of december   the company had fully drawn against the line 
in june  the company established an additional million credit line with dynamics commercial funding corp 
with lease terms of months and a rate equal to the yield on four year treasury notes 
as of december   the company had fully drawn against this line 
in november  the company established an additional million credit line with dynamics commercial funding corp  with lease terms of months and a rate equal to the yield on four year treasury notes 
as of december   approximately million was drawn against this line 
in april  the company established a million credit line with first sierra financial  inc with lease terms of months and a rate equal to the yield on four year treasury notes 
as of december   the company had fully drawn against this line 
in september  the company established an additional million credit line with first sierra financial  inc with the lease terms of months and a rate equal to the yield on four year treasury notes 
as of december   approximately  was drawn against this line 
in july  the company established a million credit line with advanced capital resources corp 
with lease terms of months and a rate equal to the yield on four year treasury notes 
as of december   approximately  was drawn against this line 
in november  the company established a million credit line with trimarc financial corp 
with lease terms of months and a rate equal to the yield on four year treasury notes 
as of december   the company had fully drawn against this line 
the company s growth strategy is anticipated to be financed through its current cash resources and existing third party credit facilities 
the company believes the combination of these sources will be sufficient to fund its operations and satisfy the company s cash requirements for the next months and the foreseeable future 
there may be circumstances  however  that would accelerate the company s use of cash resources 
if this occurs  the company may  from time to time  incur additional indebtedness or issue  in public or private transactions  equity or debt securities 
however  there can be no assurance that suitable debt or equity financing will be available to the company 
impact of inflation and changing prices the impact of inflation and changing prices on the company has been primarily limited to salary  laboratory and operating supplies and rent increases and has not been material to date to the company s operations 
in the future  the company s revenue realization per case may not be sufficient to cover the cost of inflation  although the company is responding to these concerns by attempting to increase the volume and adjust the product mix of its business 
recently issued accounting standards in june  the financial accounting standards board issued statement of financial accounting standards sfas no 
 accounting for derivative instruments and hedging activities  which  as amended  becomes effective for our financial statements beginning january  sfas no 
requires a company to recognize all derivative instruments as assets or liabilities in its balance sheet and measure them at fair value 
the company does not expect the adoption of this statement to have a material impact on the financial statements 
in december  the staff of the securities and exchange commission issued staff accounting bulletin no 
 revenue recognition in financial statements sab 
sab summarizes certain of the staff s views in applying generally accepted accounting principles to revenue recognition in financial statements 
sab requires a company to follow its guidance no later than the second quarter of its fiscal year beginning after december  through a cumulative effect of a change in accounting principles 
the company s adoption of this sab did not have a material impact on our financial statements 
item a 
quantitative and qualitative disclosures about market risk the following discussion about our exposure to market risk of financial instruments contains forward looking statements 
actual results may differ materially from those described 
our holdings of financial instruments are comprised primarily of us corporate debt  us government debt and commercial paper 
all such instruments are classified as securities available for sale 
we do not invest in portfolio equity securities or commodities or use financial derivatives for trading purposes 
our debt security portfolio represents funds held temporarily pending use in our business and operations 
we manage these funds accordingly 
we seek reasonable assuredness of the safety of principal and market liquidity by investing in rated fixed income securities while at the same time seeking to achieve a favorable rate or return 
our market risk exposure consists principally of exposure to changes in interest rates 
our holdings are also exposed to the risks of changes in the credit quality of issuers 
we typically invest in the shorter end of the maturity spectrum  and at december   more than of our holdings were in instruments maturing in two years or less and more than of such holdings matured in one year or less 

